Dr. Drilon on MET-Amplified Lung Cancer

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Many drugs, such as antibodies or tyrosine kinase inhibitors (TKIs), have been developed to target MET, states Drilon. There are specific biomarker states that are drivers of the tumors, the first being MET exon 14 splicing mutations. They are the increased expression of the MET receptor on the cell surface.

A second biomarker state is highly MET-amplified lung cancers. For both biomarkers, there is data suggesting that these tumors respond well to targeted therapy, states Drilon.